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ABSTRACT  41 
Objectives: Melioidosis, caused by Burkholderia pseudomallei, requires intensive antimicrobial 42 
treatment. However, standardised antimicrobial susceptibility testing (AST) methodology based on 43 
modern principles for determining breakpoints and ascertaining performance of methods are lacking 44 
for B. pseudomallei. This study aimed to establish MIC and zone diameter distributions on which to set 45 
epidemiological cut-off (ECOFF) values for B. pseudomallei using standard EUCAST methodology for 46 
non-fastidious organisms. 47 
Methods: Non-consecutive, non-duplicate clinical B. pseudomallei isolates (9-70 per centre) were 48 
tested at eight study centres against eight antimicrobials by broth microdilution (BMD) and the 49 
EUCAST disc diffusion method. Isolates without and with suspected resistance mechanisms were 50 
deliberately selected. The EUCAST Development Laboratory ensured the quality of study materials, 51 
provided guidance on performance of the tests and interpretation of results. Aggregated results were 52 
analysed according to EUCAST recommendations to determine ECOFFs.  53 
Results: MIC and zone diameter distributions were generated using BMD and disc diffusion results 54 
obtained for 361 B. pseudomallei isolates. MIC and zone diameter ECOFFs (mg/L–mm) were 55 
determined for amoxicillin-clavulanic acid (8–22), ceftazidime (8–22), imipenem (2–29), meropenem 56 
(2–26), doxycycline (2–none), tetracycline (8–23), chloramphenicol (8–22) and trimethoprim-57 
sulfamethoxazole (4–28).  58 
Conclusions: We have validated the use of standard BMD and disc diffusion methodology for AST of 59 
B. pseudomallei. The MIC and zone diameter distributions generated in this study allowed us to 60 
establish MIC and zone diameter ECOFFs, respectively, for the antimicrobials studied. These 61 
ECOFFs served as background data for EUCAST to set clinical MIC and zone diameter breakpoints 62 
for B. pseudomallei. 63 
 64 
Introduction 65 
  66 
Melioidosis is a bacterial infection caused by the soil saprophyte Burkholderia pseudomallei [1]. 67 
The disease is estimated to affect approximately 165,000 people each year worldwide, causing nearly 68 
90,000 deaths [2]. In some parts of the tropics, B. pseudomallei is one of the commonest isolates from 69 
clinical samples, particularly during the rainy season [3]. A series of randomised controlled trials have 70 
shown that the mortality from melioidosis can be substantially reduced by appropriate antibiotic 71 
treatment [4], and the overall mortality in northern Australia is now only approximately 10% [5]. 72 
However, if appropriate antibiotic treatment is delayed, the mortality rates may exceed 50% [6].  73 
Due to numerous intrinsic resistance mechanisms harboured by the organism, treatment 74 
options are limited and these are sometimes further challenged by acquired resistance [7]. Treatment 75 
failure due to primary resistance to therapeutic agents is a well-documented problem in B. 76 
pseudomallei infections [8] which requires laboratories to establish antimicrobial susceptibility testing 77 
(AST) methods in order to inform treatment. Since the 1940s there have been numerous studies of the 78 
in vitro action of antimicrobial agents against B. pseudomallei using either broth or agar dilution or 79 
gradient diffusion to determine minimum inhibitory concentrations (MICs) [9–15]. Laboratories in 80 
endemic areas, however, usually use disc diffusion methods for routine AST of clinical isolates. To 81 
date, there have been no internationally accepted criteria published to assist with the interpretation of 82 
such tests. The Clinical and Laboratory Standards Institute (CLSI) recommends only the broth 83 
microdilution (BMD) method for testing B. pseudomallei [16] and EUCAST have not published any 84 
recommendations for this species prior to this study. Laboratories have therefore either used 85 
interpretative criteria for other species, such as Enterobacterales, Pseudomonas aeruginosa or 86 
Burkholderia cepacia, or developed their own in-house criteria [9–15]. 87 
In order to address the need for standardised AST methodology for B. pseudomallei, we have 88 
undertaken a multi-centre study. Following consultation with clinical colleagues and careful review of 89 
the current treatment guidelines, we identified eight clinically relevant antimicrobial agents against B. 90 
pseudomallei. In this study, we aimed to establish MIC and zone diameter distributions for eight 91 
antimicrobials tested against an international collection of B. pseudomallei isolates on which to set 92 
epidemiological cut-off (ECOFF) values and interpretative criteria for AST of B. pseudomallei using 93 
EUCAST methodology for non-fastidious organisms.  94 
 95 
Methods 96 
  97 
Study design, participants 98 
Potential partners in melioidosis-endemic regions of Southeast Asia and northern Australia, 99 
together with reference laboratories in Europe experienced in testing this pathogen, were invited to 100 
take part in this multi-centre study. Since B. pseudomallei is a laboratory risk group 3 organism in most 101 
countries and a potential biothreat, all testing was planned to be performed on the sites where the 102 
organism was initially isolated or stored.  103 
The flowchart displaying the stages of the study (carried out prospectively between March 2018 104 
and January 2019) is detailed in the Supplementary material (Fig. S1). The EUCAST Development 105 
Laboratory (EDL) undertook the coordinating role in the study and ensured the quality and the 106 
representativeness of the data. Participating laboratories and numbers of isolates contributed per 107 
centre (n) were as follows: Cambodia Oxford Medical Research Unit, Cambodia (70), Mahidol-Oxford 108 
Tropical Medicine Research Unit, Thailand (65), Lao-Oxford-Mahosot Hospital-Wellcome Trust 109 
Research Unit, Lao People’s Democratic Republic (63), Royal Darwin Hospital, Australia (52), 110 
Townsville Hospital, Australia (49), Bundeswehr Institute of Microbiology, Germany (37), Robert Koch 111 
Institute, Germany (16), Public Health Agency of Sweden, Sweden (9).  112 
 113 
Pre-study exercise to introduce EUCAST disc diffusion methodology in participating centres  114 
A practical exercise was planned to introduce EUCAST disc diffusion methodology for non-115 
fastidious organisms in the participating laboratories. For this purpose, the laboratories were asked to 116 
submit disc diffusion test results for P. aeruginosa ATCC 27853 with ceftazidime (10 or 30 µg), 117 
imipenem (10 µg) and meropenem (10 µg) discs for 10 consecutive days. The participating 118 
laboratories submitted their results together with pictures of disc diffusion plates taken on the first and 119 
last day of the testing. 120 
 121 
Bacterial isolates  122 
A total of 361 non-consecutive, non-duplicate B. pseudomallei clinical isolates (without and with 123 
suspected resistance to relevant agents) originating from human infections in different geographic 124 
areas between 1986 and 2018 were selected (9-70 isolates per centre), see Supplementary material 125 
(Table S1).  126 
 127 
Species identification  128 
Participating centres had a long tradition of the isolation and identification of B. pseudomallei. A 129 
summary of methods used for identification at each centre is presented in the Supplementary material 130 
(Table S1).   131 
 132 
Antimicrobial susceptibility testing  133 
All isolates were tested with BMD in accordance with ISO 20776-1 standard [17] against 134 
amoxicillin-clavulanic acid (fixed clavulanic acid concentration at 2 mg/L), ceftazidime, imipenem, 135 
meropenem, doxycycline, tetracycline, chloramphenicol and trimethoprim-sulfamethoxazole. All 136 
isolates were tested in parallel with the EUCAST disc diffusion method for non-fastidious organisms 137 
[18,19]. Quality control (QC) of the BMD panels (Merlin Diagnostika, Bornheim-Hersel, Germany) and 138 
antimicrobial discs (Oxoid, Basingstoke, UK) was performed at the EDL before they were shipped to 139 
the participating centres where QC was repeated before testing of clinical isolates. Following a 140 
practice period, during which guidance on performance of the tests and interpretation of results was 141 
provided by EDL, each centre tested clinical isolates together with four QC strains (Escherichia coli 142 
ATCC 25922, E. coli ATCC 35218, P. aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 143 
29213). Disc diffusion AST was performed using Mueller-Hinton agar plates that were routinely used 144 
at each participating laboratory, see Supplementary material (Table S2).  145 
 146 
ECOFF determination 147 
Each centre submitted their results to the EDL on a spreadsheet where aggregated results were 148 
analysed and ECOFFs determined according to EUCAST Standard Operating Procedure (SOP) 10.1 149 
“MIC distributions and the setting of epidemiological cut-off (ECOFF) values” [20]. Consensus from 150 
visual estimation and the ECOFFinder program (version 2.1, available on the EUCAST website: 151 
https://www.eucast.org/mic_distributions_and_ecoffs/) was used to determine ECOFFs.    152 
 153 
Results  154 
 155 
The pre-study exercise with P. aeruginosa ATCC 27853 allowed the introduction of the 156 
EUCAST disc diffusion methodology in the participating centres. See Supplementary material (Table 157 
S2) for a summary of results achieved in the pre-study exercise.  158 
MIC and disc diffusion results for eight antimicrobials were collected from the eight centres for 159 
361 B. pseudomallei isolates. The pooled MIC and zone diameter distributions are displayed in Table 160 
1 and Table 2, respectively, whereas distributions for the individual centres are available in the 161 
Supplementary material (Table S3-S17).  162 
Graphs of MIC-zone diameter correlation were prepared for each antimicrobial agent (see Fig. 163 
S2–S9 in the Supplementary material). As an example, the distribution of inhibition zone diameters vs. 164 
MICs for ceftazidime is presented in Fig. 1.    165 
The MIC distribution histograms are displayed in the Supplementary material for each 166 
antimicrobial agent as (1) aggregated data from all laboratories (Fig. S10–S17) and (2) data from 167 
individual laboratories (Fig. S18–S25), respectively.    168 
ECOFFs were the consensus from visual estimation and the ECOFFinder program with one 169 
slight discrepancy of one dilution with imipenem between visual estimate (2 mg/L) and ECOFFinder 170 
program (1 mg/L). The determined ECOFF values and recently published EUCAST clinical 171 




In this multi-centre study, we validated the use of standard MIC broth microdilution and disc 176 
diffusion methodology for AST of B. pseudomallei. MIC and zone diameter ECOFFs for 361 B. 177 
pseudomallei clinical isolates were determined for eight antimicrobials. The ECOFFs and MIC 178 
distributions, served as background data for EUCAST when determining clinical MIC breakpoints and 179 
corresponding zone diameter breakpoints [21]. 180 
Current recommended treatment for all except mild localised infections is divided into two 181 
phases, the initial (intravenous intensive) phase lasts at least ten days (up to eight weeks), and the 182 
second (oral eradication) phase lasts at least 12 weeks (up to six months) [4,5]. Following a 183 
randomised controlled study published in 1989 [22], ceftazidime became the mainstay antimicrobial 184 
with carbapenems (imipenem and meropenem) as a backup option for more severe infections or 185 
treatment failures with ceftazidime [5]. Intravenous amoxicillin-clavulanic acid is an option as a 186 
second-line therapy during the initial phase where it is available [23], although it is associated with a 187 
higher rate of treatment failures. Trimethoprim-sulfamethoxazole, with amoxicillin-clavulanic acid as an 188 
alternative, remains the first-line drug for the eradication phase therapy [24].  189 
Even though primary resistance is uncommon for beta-lactam agents, emergence of 190 
resistance is a well-documented, albeit relatively rare, problem for all agents used in the treatment of 191 
melioidosis [7]. This increases the importance of performing AST of the organism before the initiation 192 
of treatment and monitoring the susceptibility of the isolate if treatment failure is suspected. However, 193 
the only recommended method for AST of B. pseudomallei is broth microdilution [16] which is 194 
cumbersome, especially when considering the high number of cases in endemic areas. The CLSI 195 
provides clinical MIC breakpoints for amoxicillin-clavulanic acid (2:1 ratio), ceftazidime, imipenem, 196 
doxycycline, tetracycline and trimethoprim-sulfamethoxazole, but not for meropenem which is the drug 197 
of choice in severe melioidosis in some centres [5], and chloramphenicol which is sometimes used in 198 
eradication therapy. 199 
Due to the lack of a practical standardised method for AST, many laboratories in endemic 200 
areas have opted to develop their own in-house criteria for disc diffusion AST of B. pseudomallei by 201 
adapting clinical breakpoints available in CLSI guidelines for Enterobacterales, P. aeruginosa and B. 202 
cepacia complex [25]. Gradient strip tests are also widely used for determination of MICs of 203 
antimicrobials listed in the CLSI guideline. However, in a recent three-centre study, poor correlation 204 
with the reference BMD method was found for tetracycline and trimethoprim-sulfamethoxazole Etest 205 
strips (bioMérieux, France) for AST of B. pseudomallei [26].   206 
Reader subjectivity and, as a consequence, difficulty in determining MIC endpoints for 207 
trimethoprim-sulfamethoxazole with B. pseudomallei was described previously [12]. In our study, 208 
investigators were advised to read the BMD MIC of trimethoprim-sulfamethoxazole at the lowest 209 
concentration that inhibited ≥80% of growth as compared to the growth control which corresponds to 210 
EUCAST and CLSI recommendations for this agent. The aggregated data from eight centres yielded 211 
an MIC distribution in which 91.4% (330/361) of isolates had an MIC between 0.25 and 2 mg/L (see 212 
Fig. S17 in the Supplementary material), showing that by standardisation of test procedures and 213 
reading practices among investigators, reader subjectivity can be minimised.  214 
The lack of standardised methodology and interpretative criteria for disc diffusion testing of 215 
trimethoprim-sulfamethoxazole with B. pseudomallei, has resulted in misleading figures for 216 
trimethoprim-sulfamethoxazole resistance in B. pseudomallei in the literature [27,28]. For example, the 217 
national antimicrobial resistance surveillance program in Thailand reported the percentage of 218 
trimethoprim-sulfamethoxazole susceptible B. pseudomallei isolates between 39.8% and 52.8% for a 219 
total of 4019 isolates collected between 2000 and 2004, which is probably misleadingly low [25]. 220 
Laboratories in the national network had submitted susceptibility data for trimethoprim-221 
sulfamethoxazole obtained by disc diffusion methods which were interpreted according to CLSI criteria 222 
published for organisms other than B. pseudomallei. The failure to follow standardised methodology 223 
resulted in erroneous data and the authors described the results as unreliable. 224 
The difficulty of reading disc diffusion results for this combination against B. pseudomallei is 225 
well known [29]. Prior to the start of the study, we requested pictures from the participating centres 226 
showing inhibition zones for B. pseudomallei with trimethoprim-sulfamethoxazole. Since the pictures 227 
often showed inhibition zones with poorly defined edges (and often with hazy growth within the zone, 228 
similar to that often observed for Stenotrophomonas maltophilia [21]), we asked all participants to read 229 
and record two zone diameters for trimethoprim-sulfamethoxazole; (1) the outer zone edge if an outer 230 
zone could be seen, and (2) an inner zone taking all growth into account (see Supplementary material 231 
Fig. S26 and specific reading instructions for B. pseudomallei in EUCAST clinical breakpoint tables 232 
[21]). Despite the reader subjectivity in determining zone edges, a satisfactory inhibition zone diameter 233 
distribution was obtained by reading the outer zone edge which showed good correlation with the 234 
MICs read at 80% inhibition. Results obtained by this specific reading method were used for analyses. 235 
In EUCAST methodology, the tetracycline disc is used to predict susceptibility to doxycycline. 236 
The good correlation between doxycycline MIC ECOFF (2 mg/L) and tetracycline zone diameter 237 
ECOFF (23 mm) shown in our study (see Supplementary material Fig. S27) enabled EUCAST to 238 
recommend disc diffusion using tetracycline 30 µg disc as a screening test to predict doxycycline 239 
susceptibility in B. pseudomallei [21].  240 
An earlier study by Maloney et al. generated MIC distributions of B. pseudomallei for 241 
ceftazidime, meropenem, doxycycline and trimethoprim-sulfamethoxazole [30]. The researchers used 242 
the reference BMD method to test 234 consecutive, clinical B. pseudomallei isolates. They produced 243 
MIC histograms for each antimicrobial agent and proposed ECOFFs by visual inspection. The 244 
ECOFFs proposed agree with our ECOFFs for ceftazidime, meropenem and trimethoprim-245 
sulfamethoxazole, but the proposed ECOFF for doxycycline is one dilution higher than our ECOFF. 246 
For a given microbial species and antimicrobial agent, the ECOFF is the highest MIC (and 247 
corresponding zone diameter) for organisms devoid of phenotypically-detectable acquired resistance 248 
mechanisms. It defines the upper end of the wild-type MIC distribution. The ECOFF provides an 249 
opportunity to compare rates of acquired resistance in situations where clinical breakpoints differ (e.g. 250 
between organisations, between humans and animals), change over time or have not been set. Our 251 
data meet the criteria in the EUCAST SOP for defining MIC wild-type distributions and determining 252 
ECOFFs [20]. Obtaining MIC distributions from eight centres ensured that inter-laboratory variation 253 
was factored into the definition of the reference MIC distribution. The aggregated MIC distributions for 254 
each antimicrobial contained >100 MIC values in the putative wild-type distribution and >15 MIC 255 
values were available for each antimicrobial from seven participating centres. Since the data 256 
generated in this study fulfilled the standardised criteria for setting ECOFFs, we managed to establish 257 
ECOFFs for all targeted antimicrobials listed in Table 3.  258 
Similarly, the zone diameter distributions generated in this study allowed us to establish zone 259 
diameter ECOFFs for all antimicrobials included in the study. This also enabled us to demonstrate that 260 
EUCAST standard disc diffusion methodology for non-fastidious organisms is applicable for B. 261 
pseudomallei.  262 
The treatment of infections with B. pseudomallei requires high doses of antimicrobial agents. 263 
This is reflected by the fact that most wild-type isolates would be placed in the second EUCAST 264 
susceptible category, “susceptible, increased exposure (I)”, and should therefore be reported “I”, the 265 
exceptions being imipenem and meropenem. Laboratories adopting this approach will need to devote 266 
time and resources to educating clinicians in how to interpret laboratory reports of susceptibility of the 267 
species. 268 
Finally, it is important to note that the proportion of non-wild-type organisms in our collection 269 
appears spuriously high because a disproportionately high number of isolates with in vitro 270 
antimicrobial resistance were deliberately included in this study, thus the distributions in our study 271 




 The MIC and zone diameter ECOFFs determined in this study formed the basis for EUCAST 276 
MIC and zone diameter breakpoints for B. pseudomallei in the most recent version of EUCAST clinical 277 
breakpoint tables [21]. Determination of MICs is a costly procedure in many low and middle income 278 
countries, whereas disc diffusion serves as a cost-effective alternative. We conclude that by 279 
implementing the EUCAST standard disc diffusion methodology for B. pseudomallei, laboratories in 280 
endemic regions where disc diffusion is used routinely will be able to test and report susceptibility 281 
results for B. pseudomallei. 282 
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Table 1. Minimum inhibitory concentration (MIC) distributions for B. pseudomallei isolates (n = 361; aggregated data from eight centres)   
 MIC (mg/L) 
Antimicrobial agent 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128 
Amoxicillin-clavulanic acid*    2 6 140 165 15 3 3 5 34 
Ceftazidime    1 9 116 189 14 22 5 17  
Imipenem  9 58 209 70 18 6 1  2   
Meropenem    73 232 60 7 1     
Doxycycline  2 52 195 84 18 8 7 7    
Tetracycline    23 96 175 59 9 8 3   
Chloramphenicol     1 55 267 31 3 3 13  
Trimethoprim-sulfamethoxazole 2 8 32 127 136 47 6 6 8 1   
Underlined = the mode of respective distribution. 
Bold underlined = truncation (higher than the highest concentration on the MIC panel). 











Table 2.  Zone diameter distributions for B. pseudomallei isolates (n = 361; aggregated data from eight centres)   
Antimicrobial agent Disk content (µg) 
  Zone diameter (mm) 
  6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 
Amoxicillin-clavulanic acid 20-10   8     3 5 1 6 2 4 3   3 4 6 8 5 3 5 19 31 59 64 78 31 13                                         
Ceftazidime 10   23   2 2 4 5 3 4 7 3 3   2 3 7 7 12 17 31 60 65 68 27 6                                           
Imipenem 10                     2 2   4   4 2 3 6 2   2     2 6 2 12 7 37 55 61 49 50 20 21 5 6   1             
Meropenem 10               1       1 3 5 3 7 14 10 9 16 11 16 14 34 39 55 53 51 17 2                                 
Tetracycline 30   1             3 2 2 3   3 2 4 6 5 13 26 60 65 62 52 21 17 7 6   1                                 
Chloramphenicol 30   16   1       1     1 1   1 1 2 1 2 15 36 77 59 55 39 26 18 6 2       1                             
Trimethoprim-sulfamethoxazole 1.25-23.75   17       2 1 1 3 2 1   1 8 2 10 4 7 6 12 20 24 19 31 15 31 6 26 33 32 27 13 4     2   1                 












Table 3. Epidemiological cut-off (ECOFF) values for B. pseudomallei based on minimum inhibitory concentration (MIC) and disc diffusion data on 361 observations for each 
antimicrobial agent. For reference, MIC and zone diameter clinical breakpoints set by EUCAST are listed. 
 
MIC and zone diameter ECOFFs for B. 
pseudomallei determined in this study 
 
EUCAST MIC and zone diameter clinical 
















S ≤ R > S ≥ R < 
Amoxicillin-clavulanic acid 8 20-10 22  0.001 8 50 22 
Ceftazidime 8 10 22  0.001 8 50 18 
Imipenem 2 10 29  2 2 29 29 
Meropenem 2 10 26  2 2 24 24 
Doxycycline 2 - Note*  0.001 2 Note* Note* 
Tetracycline 8 30 23  NA NA 50 23 
Chloramphenicol 8 30 22  0.001 8 50 22 
Trimethoprim-sulfamethoxazole 4 1.25-23.75 28  0.001 4 50 17 
NA: Not applicable. 
* In EUCAST methodology, tetracycline disc diffusion is used to infer doxycycline susceptibility. 
 
Fig. 1. Ceftazidime (10 µg disc) inhibition zone diameter distribution for B. pseudomallei isolates (n = 361; aggregated data from eight centres). Corresponding minimum 
inhibitory concentration (MIC) values are shown through the colouring of bars. The colours correspond to EUCAST ceftazidime MIC breakpoints for B. pseudomallei (S ≤ 
0.001 mg/L, R > 8 mg/L): I = yellow and R = orange/red. 
